What is the translation of " NUSPOJAVE NA LIJEK " in English?

• adverse drug reactions
• adrs

Examples of using Nuspojave na lijek in Croatian and their translations into English

Tablica 1: Vrlo česte nuspojave na lijek u ispitivanju BR.21.
Table 1: Very common ADRs in study BR.21.

Nuspojave na lijek specifične za ostatne tvari iz proizvodnog postupka.
ADRs specific to residues from the manufacturing process.

Tablica 3: Vrlo česte nuspojave na lijek u ispitivanju LUX-Lung 3.
Table 3: Very common ADRs in trial LUX-Lung 3.

Bili ste u pravu doktore, postoje nuspojave na lijek.
You were right, Doctor-- there are side effects to the drug.

Nisu prijavljene nuspojave na lijek s apsolutnom razlikom od ≥15.
No adverse drug reactions were reported with an absolute difference of≥15.

Ukupno je 32,2% bolesnika imalo nuspojave na lijek.
Overall 32.2% of the patients experienced adverse drug reactions.

Tablica 3: Vrlo česte nuspojave na lijek u ispitivanju PA.3 kohorta koja je primala 100 mg.
Table 3: Very common ADRs in study PA.3 100 mg cohort.

Upitnik za prikupljanje detaljne dokumentacije o prijavi nuspojave na lijek.
A questionnaire to gather detailed ADR report documentation.

Nuspojave na lijek prijavljivane su koristeći se NCI-CTCAE kriterijima za ocjenu toksičnosti.
ADRs were reported using NCI-CTCAE for assessment of toxicity.

Najčešće prijavljene ili opažene ozbiljne nuspojave na lijek bile su.
The most frequent reported or observed serious adverse drug reactions were.

Najčešće prijavljene nuspojave na lijek bile su trombocitopenija i anemija.
The most frequently reported adverse drug reactions were thrombocytopenia and anaemia.

Nuspojave na lijek određene su na temelju podataka dobivenih u programu kliničkog razvoja apremilasta.
The adverse drug reactions were determined based on data from the apremilast clinical development programme.

Tri najučestalije nehematološke nuspojave na lijek bile su modrice(21,3%), omaglica(15,3%) i glavobolja 14, 0.
The three most frequent non-haematological adverse drug reactions were bruising(21.3%), dizziness(15.3%) and headache 14.0.

Nuspojave na lijek temeljene na udruženim podacima prikazane prema klasifikaciji organskih sustava i preporučenim izrazima su niže navedene.
Adverse drug reactions(ADRs) based upon pooled data are shown by system, organ class and by preferred term are listed below.

Liječenje Jakavijem može uzrokovati hematološke nuspojave na lijek, koje uključuju trombocitopeniju, anemiju i neutropeniju.
Treatment with Jakavi can cause haematological adverse drug reactions, including thrombocytopenia, anaemia and neutropenia.

Tablica 4: Nuspojave na lijek nakon stavljanja lijeka u promet prijavljene u bolesnika liječenih lenalidomidom.
Table 4: ADRs reported in post-marketing use in patients treated with lenalidomide.

Algoritam primijenjen da bi nuspojava bila uključena u sažetak opisa svojstava lijeka(SmPC): sve nuspojave na lijek zabilježene prema algoritmu za ispitivanje faze III uključene su u EU SmPC.
Algorithm applied for inclusion in the SmPC: All ADRs captured by the Phase III study algorithm are included in the EU SmPC.

Prijavljene nuspojave na lijek u nastavku su navedene prema MedDRA klasifikaciji organskih sustava i učestalosti.
ADRs which were reported are listed below by MedDRA body system organ class and by frequency.

Druge prijavljene ozbiljne nuspojave na lijek uključuju reaktivaciju hepatitisa B i PML vidjeti dio 4.4.
Other serious ADRs reported include hepatitis B reactivation and PML see section 4.4.

Nuspojave na lijek primijećene tijekom ili unutar 24 sata nakon infekcije u načelu su bile slične naravi kao one zabilježene kod bolesnika s RA i sJIA, vidjeti dio 4.8.
In general, the adverse drug reactions observed during or within 24 hours of an infusion were similar in nature to those seen in RA and sJIA patients, see section 4.8.

Unutar svakog organskog sustava, nuspojave na lijek su poredane po učestalosti, pri čemu su najučestalije nuspojave navedene prve.
Within each system organ class, the adverse drug reactions are ranked by frequency, with the most frequent reactions first.

Nuspojave na lijek povezane s povišenim razinama kreatinina su grupirane npr. smanjen bubrežni klirens kreatinina, oštećenje bubrežne funkcije, povišenje razine kreatinina u krvi i smanjena brzina glomerularne filtracije.
Adverse drug reactions related to increased creatinine were grouped e.g. decreased renal creatinine clearance, renal impairment, increased blood creatinine and decreased glomerular filtration rate.

Kod svinja su ozbiljne nuspojave na lijek nakon upotrebe Econora uglavnom bile povezane s pasminama i hibridima danskog i/ili švedskog landrasa.
In pigs, serious adverse drug reactions following the use of Econor are mainly associated with breeds and cross breeds of Danish and/or Swedish Landrace.

Vrlo česte nuspojave na lijek u bolesnika liječenih GIOTRIFOM koje su se javile kod najmanje 10% bolesnika u ispitivanju LUX-Lung 3 prikazane su u tablici 3 prema stupnjevima Zajedničkih kriterija toksičnosti Nacionalnog instituta za rak NCI-CTC.
Very common ADRs in GIOTRIF-treated patients occurring in at least 10% of patients in trial LUX-Lung 3 are summarised by National Cancer Institute-Common Toxicity Criteria(NCI-CTC) Grade in Table 3.

Najčešće prijavljene nuspojave na lijek, specifične za nintedanib, bile su proljev, povećane vrijednosti jetrenih enzima(ALT i AST) te povraćanje.
The most frequently reported adverse drug reactions(ADRs) specific for nintedanib were diarrhoea, increased liver enzyme values(ALT and AST) and vomiting.

Nuspojave na lijek navedene u nastavku obuhvaćaju početno razdoblje ispitivanja(do 32. tjedna) s ekvivalentnom izloženošću ruksolitinibu i najboljoj dostupnoj terapiji(NDT), što odgovara medijanu trajanja izloženosti Jakaviju od 7, 8 mjeseci.
The adverse drug reactions listed below reflect the initial study period(up to week 32) with equivalent exposure to ruxolitinib and Best Available Therapy(BAT), corresponding to a median duration of exposure to Jakavi of 7.8 months.

Najčešće uočene nuspojave na lijek u bolesnika liječenih delamanidom(primjerice, incidencija> 10%) su mučnina(38,3%), povraćanje(33%) i omaglica 30, 2.
The most frequently observed adverse drug reactions in patients treated with delamanid(i.e. incidence> 10%) are nausea(38.3%), vomiting(33%), and dizziness 30.2.

Najčešće nuspojave na lijek bile su proljev i nuspojave povezane s kožom(vidjeti dio 4.4) kao i stomatitis, te paronihija vidjeti također tablicu 3 i 4.
The most frequent ADRs were diarrhoea and skin related adverse events(see section 4.4) as well as stomatitis and paronychia see also Table 3 and 4.

Najučestalije nuspojave na lijek( 15%) prijavljene pri uporabi dabrafeniba bile su hiperkeratoza, glavobolja, pireksija, artralgija, umor, mučnina, papilom, alopecija, osip i povraćanje.
The most frequently occurring adverse drug reactions(ADRs)(15%) reported with dabrafenib were hyperkeratosis, headache, pyrexia, arthralgia, fatigue, nausea, papilloma, alopecia, rash and vomiting.

Najčešće primijećene nuspojave na lijek u bolesnika liječenih ofatumumabom u kliničkim ispitivanjima bile su reakcije povezane s infuzijom, koje su se javile u 68%(348/511) bolesnika u nekom trenutku tijekom liječenja.
The most frequently observed ADRs in patients receiving Arzerra in clinical trials were infusion- related reactions which occurred in 68%(348/511) of patients at any time during treatment.